erlotinib + panitumumab

Erlotinib + panitumumab is a combination of two targeted anticancer agents that both inhibit the epidermal growth factor receptor (EGFR) but through different mechanisms. Erlotinib is a small molecule tyrosine kinase inhibitor that blocks the intracellular kinase domain of EGFR, preventing autophosphorylation and downstream signaling involved in tumor cell proliferation and survival. Panitumumab is a fully human monoclonal antibody that binds to the extracellular domain of EGFR, blocking ligand binding and receptor activation. This dual blockade approach has been investigated for synergistic antitumor effects in cancers where EGFR signaling drives disease progression, such as metastatic pancreatic adenocarcinoma and colorectal cancer[1][2][4]. Clinical trials have shown increased toxicity with this combination compared to single-agent or standard regimens[1][2].